| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 40 | 2023 | 5317 | 2.280 |
Why?
|
| Nitric Oxide Synthase Type II | 13 | 2017 | 261 | 1.780 |
Why?
|
| Intramolecular Oxidoreductases | 4 | 2023 | 81 | 1.360 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2022 | 182 | 1.320 |
Why?
|
| Interleukins | 10 | 2011 | 325 | 1.210 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 3 | 2022 | 34 | 1.100 |
Why?
|
| Nitric Oxide | 8 | 2014 | 644 | 0.960 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 2864 | 0.860 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2022 | 47 | 0.760 |
Why?
|
| Immunotherapy | 5 | 2023 | 3341 | 0.650 |
Why?
|
| Skin Neoplasms | 12 | 2021 | 4654 | 0.640 |
Why?
|
| Prostaglandin-E Synthases | 3 | 2023 | 28 | 0.540 |
Why?
|
| Cyclooxygenase 2 | 4 | 2023 | 483 | 0.530 |
Why?
|
| Apoptosis | 16 | 2013 | 7591 | 0.520 |
Why?
|
| Nitric Oxide Synthase | 5 | 2005 | 314 | 0.470 |
Why?
|
| Interferon-gamma | 5 | 2024 | 1144 | 0.470 |
Why?
|
| Neoplasms | 9 | 2022 | 15193 | 0.430 |
Why?
|
| Signal Transduction | 16 | 2022 | 11965 | 0.420 |
Why?
|
| Cell Proliferation | 12 | 2022 | 7226 | 0.410 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 105 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2018 | 8873 | 0.400 |
Why?
|
| Chemokines | 1 | 2011 | 314 | 0.370 |
Why?
|
| Plant Extracts | 1 | 2011 | 215 | 0.340 |
Why?
|
| Inflammation | 4 | 2015 | 2522 | 0.330 |
Why?
|
| Autophagy | 2 | 2012 | 927 | 0.320 |
Why?
|
| Receptors, Interleukin | 2 | 2006 | 97 | 0.320 |
Why?
|
| Interferon-beta | 1 | 2008 | 102 | 0.320 |
Why?
|
| Interleukin-10 | 4 | 2006 | 478 | 0.300 |
Why?
|
| Dinoprostone | 3 | 2023 | 208 | 0.280 |
Why?
|
| Interferon-alpha | 2 | 2008 | 889 | 0.270 |
Why?
|
| Cell Line, Tumor | 21 | 2018 | 14551 | 0.260 |
Why?
|
| Bystander Effect | 1 | 2004 | 23 | 0.260 |
Why?
|
| Immunohistochemistry | 9 | 2016 | 7548 | 0.250 |
Why?
|
| Tyrosine | 2 | 2008 | 498 | 0.240 |
Why?
|
| Adenoviridae | 3 | 2005 | 1459 | 0.240 |
Why?
|
| Cyclooxygenase 1 | 1 | 2023 | 67 | 0.230 |
Why?
|
| Sulfonamides | 3 | 2024 | 1823 | 0.210 |
Why?
|
| Melanocytes | 2 | 2012 | 219 | 0.210 |
Why?
|
| Interleukin-1beta | 2 | 2015 | 300 | 0.210 |
Why?
|
| Humans | 55 | 2024 | 261506 | 0.210 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10331 | 0.200 |
Why?
|
| Growth Substances | 1 | 2001 | 300 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 5395 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 5159 | 0.190 |
Why?
|
| Blotting, Western | 6 | 2015 | 3536 | 0.190 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2005 | 1064 | 0.180 |
Why?
|
| Collagen | 1 | 2023 | 752 | 0.180 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 14289 | 0.180 |
Why?
|
| Cell Survival | 7 | 2016 | 3045 | 0.180 |
Why?
|
| Genes, ras | 3 | 2012 | 667 | 0.170 |
Why?
|
| Disease Progression | 8 | 2017 | 6682 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2016 | 1283 | 0.170 |
Why?
|
| Trans-Activators | 2 | 2005 | 1555 | 0.170 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 1879 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.160 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2017 | 2 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2021 | 351 | 0.160 |
Why?
|
| Interleukin-6 | 3 | 2022 | 1038 | 0.150 |
Why?
|
| Quinazolines | 2 | 2014 | 923 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1048 | 0.150 |
Why?
|
| Cell Cycle | 3 | 2011 | 2084 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2016 | 2054 | 0.140 |
Why?
|
| Microsomes | 1 | 2016 | 61 | 0.140 |
Why?
|
| Animals | 15 | 2023 | 59536 | 0.140 |
Why?
|
| Phosphorylation | 7 | 2016 | 4804 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 203 | 0.130 |
Why?
|
| Sialyltransferases | 1 | 2015 | 23 | 0.130 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 89 | 0.130 |
Why?
|
| Indoles | 3 | 2016 | 1009 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2017 | 403 | 0.130 |
Why?
|
| Drug Design | 2 | 2014 | 375 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2022 | 649 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.120 |
Why?
|
| Wilms Tumor | 1 | 2017 | 292 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 1073 | 0.120 |
Why?
|
| Amidohydrolases | 1 | 2014 | 25 | 0.120 |
Why?
|
| Ornithine | 1 | 2014 | 40 | 0.120 |
Why?
|
| Mice | 10 | 2023 | 34495 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 301 | 0.120 |
Why?
|
| Hypoxia | 1 | 2016 | 443 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 1998 | 1046 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.110 |
Why?
|
| RNA Interference | 3 | 2012 | 1408 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2016 | 419 | 0.110 |
Why?
|
| Cell Death | 3 | 2012 | 671 | 0.110 |
Why?
|
| Immunotoxins | 1 | 2012 | 117 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 184 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 1506 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 509 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 56 | 0.110 |
Why?
|
| Oleanolic Acid | 1 | 2012 | 108 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2006 | 703 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 717 | 0.100 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 5112 | 0.100 |
Why?
|
| DNA Primers | 2 | 2011 | 1399 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 3552 | 0.100 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2011 | 38 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 216 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 177 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 252 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2017 | 2359 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2016 | 6150 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2011 | 3033 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 13658 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 110 | 0.090 |
Why?
|
| Interleukin-1 | 1 | 2011 | 461 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5178 | 0.090 |
Why?
|
| Gene Transfer Techniques | 2 | 2011 | 716 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2015 | 1385 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2008 | 1121 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2014 | 2450 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2291 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 10001 | 0.090 |
Why?
|
| Middle Aged | 10 | 2021 | 86204 | 0.090 |
Why?
|
| Dacarbazine | 2 | 2008 | 485 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3821 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 461 | 0.090 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 69 | 0.080 |
Why?
|
| Aged | 8 | 2021 | 70117 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 29902 | 0.080 |
Why?
|
| Prognosis | 5 | 2024 | 21713 | 0.080 |
Why?
|
| RNA, Small Interfering | 5 | 2014 | 2216 | 0.080 |
Why?
|
| Adult | 8 | 2021 | 77950 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 3 | 2018 | 1077 | 0.080 |
Why?
|
| Lysine | 1 | 2010 | 422 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.080 |
Why?
|
| Female | 15 | 2021 | 141928 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 1533 | 0.080 |
Why?
|
| Base Sequence | 2 | 2011 | 4917 | 0.070 |
Why?
|
| Male | 11 | 2021 | 123000 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2004 | 323 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1763 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.070 |
Why?
|
| Cytokines | 3 | 2018 | 2809 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2008 | 626 | 0.070 |
Why?
|
| Cell Division | 4 | 2006 | 2489 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2005 | 1694 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 460 | 0.070 |
Why?
|
| Transglutaminases | 1 | 2006 | 99 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 1823 | 0.070 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 423 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2011 | 2074 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 1724 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 588 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 259 | 0.060 |
Why?
|
| Cisplatin | 2 | 2010 | 2432 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1331 | 0.060 |
Why?
|
| G2 Phase | 2 | 2004 | 206 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 280 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 566 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 6915 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 1053 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2005 | 1616 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2016 | 142 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 7222 | 0.060 |
Why?
|
| eIF-2 Kinase | 1 | 2004 | 164 | 0.060 |
Why?
|
| Curcumin | 1 | 2004 | 117 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 657 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2003 | 53 | 0.060 |
Why?
|
| Monocytes | 1 | 2006 | 788 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2012 | 1549 | 0.050 |
Why?
|
| Fenretinide | 1 | 2002 | 96 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2018 | 1313 | 0.050 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2016 | 1016 | 0.050 |
Why?
|
| Child | 3 | 2016 | 29154 | 0.050 |
Why?
|
| Transgenes | 2 | 2005 | 557 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 160 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 269 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5437 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 5114 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 299 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 4757 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 4938 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 756 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2101 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 652 | 0.040 |
Why?
|
| Mitosis | 1 | 2001 | 615 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5061 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 176 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 150 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 311 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 6207 | 0.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 923 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 4849 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 37905 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2003 | 1152 | 0.040 |
Why?
|
| Wrist | 1 | 2016 | 26 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2018 | 251 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2017 | 107 | 0.040 |
Why?
|
| WT1 Proteins | 1 | 2017 | 106 | 0.040 |
Why?
|
| Nitric Oxide Donors | 1 | 2016 | 51 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 3230 | 0.030 |
Why?
|
| Mutation | 5 | 2017 | 15179 | 0.030 |
Why?
|
| Survival Rate | 2 | 2006 | 12221 | 0.030 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Etoposide | 1 | 1998 | 870 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1999 | 842 | 0.030 |
Why?
|
| Models, Biological | 2 | 2017 | 3254 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 250 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
| Exons | 1 | 1998 | 1328 | 0.030 |
Why?
|
| Pedigree | 1 | 1998 | 1890 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 677 | 0.030 |
Why?
|
| Nitrosation | 1 | 2014 | 10 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2015 | 144 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2014 | 171 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8865 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1995 | 383 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 242 | 0.030 |
Why?
|
| TWEAK Receptor | 1 | 2012 | 3 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 852 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 1910 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 183 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2014 | 32848 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 240 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1995 | 419 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 3639 | 0.030 |
Why?
|
| Oncogenes | 1 | 2015 | 673 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 3472 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 931 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1489 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 15862 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1688 | 0.030 |
Why?
|
| Software | 1 | 2018 | 1321 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 324 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2015 | 1764 | 0.020 |
Why?
|
| Sulfones | 1 | 2012 | 143 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 2483 | 0.020 |
Why?
|
| Gene Expression | 2 | 2015 | 3570 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2001 | 4078 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2010 | 77 | 0.020 |
Why?
|
| Child, Preschool | 2 | 1998 | 16273 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 938 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2006 | 15694 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1130 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 803 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2011 | 388 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 607 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 1959 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3443 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2003 | 5270 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 4307 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 3101 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 2314 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 905 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 5710 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2006 | 82 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4844 | 0.020 |
Why?
|
| Time Factors | 1 | 2000 | 12926 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2006 | 74 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 760 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 213 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2006 | 34 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 304 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 2944 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3438 | 0.020 |
Why?
|
| Fibronectins | 1 | 2006 | 197 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1869 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 891 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2005 | 14 | 0.020 |
Why?
|
| Albumins | 1 | 2006 | 258 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1995 | 6100 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 591 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 321 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2004 | 23 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 842 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1678 | 0.020 |
Why?
|
| Injections | 1 | 2005 | 285 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2004 | 126 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1665 | 0.010 |
Why?
|
| Cell Movement | 1 | 2012 | 2466 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 1062 | 0.010 |
Why?
|
| Sarcoma | 1 | 2014 | 1725 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 471 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 2002 | 34 | 0.010 |
Why?
|
| Benzamides | 1 | 2008 | 1832 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 528 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 850 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 492 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6009 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 734 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 661 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| United States | 1 | 2018 | 15433 | 0.010 |
Why?
|
| Virus Replication | 1 | 2005 | 709 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2004 | 534 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1538 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 688 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 3203 | 0.010 |
Why?
|
| Infant | 1 | 1995 | 13310 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 6942 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 876 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1998 | 385 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 2045 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 4053 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 5047 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 3001 | 0.010 |
Why?
|